A decision by the Trump administration to withdraw a proposed Food and Drug Administration rule requiring asbestos testing for talc-based cosmetic products has opened a new front in the debate over public health policy, corporate influence and the future of Health Secretary Robert F. Kennedy Jr.'s "Make America Healthy Again" agenda.
The withdrawal, published in the Federal Register on Nov. 25, 2025, has drawn renewed scrutiny after reports alleging that senior officials within the Department of Health and Human Services were caught off guard by the decision and that Johnson & Johnson representatives had met with White House officials before the proposal was abandoned. Administration officials have disputed suggestions that the rule was improperly handled, maintaining that the regulatory process followed normal procedures.
The episode has become a focal point in broader tensions between supporters of President Donald Trump's deregulatory agenda and advocates aligned with Kennedy's health-focused policy platform, which has emphasized tighter oversight of chemicals, food additives and consumer products.
The proposed regulation originated during the Biden administration as part of the Modernization of Cosmetics Regulation Act of 2022. Published in late December 2024, the proposal sought to establish standardized methods for detecting asbestos contamination in talc used in cosmetic products.
Under the proposal, manufacturers would have been required to test talc or its raw ingredients before production and maintain documentation demonstrating compliance with federal standards. Federal regulators argued that uniform testing methods would improve product safety and create consistent industry requirements.
Instead, the FDA formally withdrew the proposal in November 2025.
According to reporting based on internal records and interviews with dozens of sources, some officials within Kennedy's department were unaware the withdrawal was imminent. Those reports alleged that senior aides attempted to determine who initiated the reversal after the document appeared on the agency's public inspection list.
The same reporting further alleged that White House lawyers and the Office of Management and Budget played central roles in revising or withdrawing the proposal after Johnson & Johnson executives visited the White House. Two senior administration officials rejected suggestions of improper influence, stating that the proposal "went through the process it's supposed to go through" and noting that the Office of Management and Budget routinely reviews federal regulations before publication.
The timing of the withdrawal also attracted attention because of its appearance in ongoing litigation involving Johnson & Johnson.
According to court records cited in the reporting, a company attorney referenced the FDA's decision during a California trial only hours after the withdrawal appeared publicly, using it to challenge testimony regarding asbestos exposure and talc products. Johnson & Johnson ultimately prevailed in that case, with the jury finding the company had not acted negligently.
The company continues to deny allegations that its talc products caused cancer.
On its corporate information page, Johnson & Johnson states that decades of scientific testing demonstrate its talc products "do not contain asbestos and do not cause cancer." Company representatives have also argued that the withdrawn FDA proposal contained significant scientific and procedural shortcomings and should not have advanced in its original form.
The controversy extends beyond one regulation because of what critics view as a broader shift in the administration's health policy priorities.
Observers have pointed to other policy decisions that appeared to diverge from positions Kennedy had advocated before joining the administration. Among them was President Trump's executive order identifying glyphosate as strategically important to American agriculture and directing agencies not to undermine the commercial viability of manufacturers producing the herbicide. Kennedy had previously criticized glyphosate during his years as an environmental attorney.
Additional questions emerged after reports that the White House encouraged the FDA to approve certain flavored vaping products shortly after a subsidiary of R.J. Reynolds contributed to a pro-Trump political action committee. Those reports were followed by the resignation of FDA Commissioner Marty Makary and several other officials associated with Kennedy's health agenda.
Administration officials have consistently rejected suggestions of conflict between Trump's political movement and Kennedy's public-health platform.
White House spokesman Kush Desai has publicly characterized the Make America Healthy Again initiative and the broader MAGA agenda as complementary rather than competing priorities. Administration officials also maintain that regulatory decisions are based on scientific review and established legal procedures rather than outside political or corporate pressure.
